Pharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
Key Highlights
- ➤CHAPTER-3 reduced monthly HAE attack rates 83% versus placebo across all HAE types
- ➤CHAPTER-3 reduced attacks 87% versus placebo in HAE Type 1 or 2
- ➤45% of deucrictibant XR participants remained attack-free for 24 weeks
- ➤CHAPTER-3 met primary and all secondary efficacy endpoints with statistical significance
- ➤HAE-related costs rose to $240,064 per patient annually during follow-up
Expert Statements
Peng Lu, President of Pharvaris
“This first opportunity to share CHAPTER-3 primary data with the medical community in the setting of a large scientific conference represents an important milestone in deucrictibant’s clinical development, with once-daily oral deucrictibant XR demonstrating reductions in the HAE attack rate in the range of those observed with injectable long-term prophylactic therapies, and nearly half of participants remaining attack-free over the entire 24-week treatment period.”
Peng Lu, President of Pharvaris
“When considered alongside the wealth of data being presented at ACAAI across our on-demand and prophylaxis clinical programs, as well as data exploring the economic burden of HAE to the healthcare system, these findings strengthen our belief in deucrictibant’s potential to address unmet needs and to change how people living with bradykinin-mediated angioedema manage their disease.”
Peng Lu, President of Pharvaris
“Our ambition is to provide the community with effective and well-tolerated oral treatment options designed with the objective of addressing patients’ needs, whether to prevent attacks or to treat them when they occur, and ultimately to lessen the impact of this unpredictable disease on everyday life and healthcare systems.”
* Phase 3 CHAPTER-3 results to be presented in the Distinguished Industry and Late-breaking Oral Abstracts sessions on Saturday, November 14, from 4:30-6:00 p.m. MST * CHAPTER-3 met the primary and all secondary efficacy endpoints with statistical significance, confirming deucrictibant XR’s potential for the prevention of HAE attacks * Deucrictibant XR reduced the monthly attack rate by 83% in all HAE types and 87% in HAE Type 1 or 2 vs. placebo and was generally well tolerated ZUG, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris(Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the oral and poster presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting, taking place November 12-16, 2026, in Phoenix, Arizona. The presentations include late-breaking results from the Phase 3 CHAPTER-3 study evaluating investigational oral deucrictibant extended-release (XR) tablet for prophylaxis of HAE attacks to be presented in the Distinguished Industry and Late-breaking Oral Abstracts sessions on Saturday, November 14 from 4:30 – 6:00 p.m. MST, as well as final long-term results from the prophylaxis Phase 2 open-label extension, additional analyses of the pivotal Phase 3 on-demand treatment study, clinical pharmacology data supporting the potential combined use of the XR and immediate-release (IR) formulations, a comprehensive assessment of deucrictibant’s cardiovascular safety across the development program, and the real-world economic burden of HAE.
Get started
Create a free account to read the full story.